Abstract

Background
The efficacy of raltegravir plus optimized background therapy (OBT) has been demonstrated for antiretroviral (ARV)-experienced
HIV-1 infected patients in randomized clinical trials. We studied viro-immunological response, pharmacokinetic parameters, and genotypic test results in an observational cohort of multiple ARV class-experienced patients starting a raltegravir-based regimen.
Methods
Already enrolled ANRS CO3 Aquitaine Cohort patients with virologic failure were included in this study after starting a raltegravir-based regimen (400 mg twice a day, week 0). Virologic success was defined by plasma HIV-1 RNA level viral load (VL) [ ] <2.7 log copies/mL at week 12 and <1.7 log copies/mL at week 24. One patient was excluded from further analysis (no follow-up 10 10 after week 4). 
Results
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10
Introduction
Raltegravir is a HIV-1 integrase inhibitor which has been successfully used in both treatment-na ve patients and heavily treated
We studied the viro-immunological response of raltegravir with optimised background therapy (OBT) in an observational prospective cohort of multiple antiretroviral class experienced patients under clinical routine conditions. Furthermore, we evaluated pharmacokinetic (PK) parameters, genotypic test results of integrase, reverse transcriptase and protease genes at baseline and in failing patients.
Patients and Methods
Study population
The 
Virological and immunological outcomes
Virological success was defined as plasma VL <2.7 log copies/mL at week 12 and <1.7 log copies/mL at week 24, quantified using 10 10 the CobasTaqman HIV assay (Roche Diagnostics, Basel, Switzerland). Patients with missing VL values at week 24 were considered as virologic success if the VL was <2.7 log copies/mL at week 12. One patient had no follow up visit after week 4 and was excluded from 10 further analysis. A poor immune response was defined as a gain of CD4 cells 50 cells/mm from week 0 to week 24.
Genotype-resistance testing
Sequencing procedures used for reverse transcriptase, protease and integrase are available on the HIV French resistance website4
Complete integrase gene sequence was determined at baseline, and in patients with virologic failure. We calculated the genotypic sensitivity score (GSS) that represents the sum of genotypic sensitivities (according to the ANRS genotype-interpretation algorithm) to the drugs in the OBT.
Determination of plasma Raltegravir concentrations
Blood samples were drawn to determine plasma raltegravir concentrations at the PK steady-state 4 weeks after starting raltegravir as well as at week 12 and week 24. Minimum (C ) and maximum (C ) serum drug concentrations, corresponding to around 12 h and 3 h min max after raltegravir ingestion, respectively, were measured using a validated HPLC with mass spectrometry detection . 5
Statistical analyses
Analyses were performed using SAS 9.1 (SAS Institute, Inc., Cary, NC 
Results
Baseline patient characteristics
The baseline characteristics of the 51 patients enrolled in this observational cohort study are reported in . Most of the patients prescribed as OBT were ritonavir-boosted darunavir (n 36, 71 ), etravirine (n 22, 43 ) and enfurvitide (n 13, 28 ). Raltegravir in
combination with ritonavir-boosted darunavir and etravirine was prescribed in 15 patients (29 ). The most frequently NRTIs % co-prescribed with raltegravir were tenofovir (n 20, 39 ), emtricitabine (n 18, 35 ) or lamivudine (n 11, 22 ).
Responses to the raltegravir containing therapy
Virological response
Virologic success was observed for 39 patients (78 ) ( ). According to a GSS of <1, 1 2 and 2 virologic success occurred in % Table 2 − 
Emerging integrase mutations
Four different patterns of emerging mutations were observed: i) five patients presented the emergence of Q148H/R with secondary mutations (V72I, L74M, G140A/S, E138A, K156N, K160N, V201I and T206S), ii) the N155S/H mutation emerged in three patients and was replaced in the following three to five month by a pattern including the mutation Y143C/H/R and secondary mutations (L74M, T97A, G163R, V151I, S230R), iii) the S230R mutation was selected in one patient and iv) two patients had virologic failure without emerging mutations.
Discussion
We observed a potent antiretroviral effect in patients failing multiple previous antiretroviral regimens before. Our findings were comparable with virological success rates observed in similar populations with heavily treatment-experienced patients , on 2 3 raltegravir-based HAART. Despite a rapid VL suppression, the overall median CD4 cell rise was 57 (0; 156)/mm between baseline and Factors associated with virological response at week 24 were the VL at baseline and the nadir of CD4 cell counts. These findings are + in agreement with the fact that most of the patients were already in an advanced disease stage.
The high proportion of integrase resistance mutations that developed in patients who failed therapy (9/11, 82 ) in this study was % consistent with findings in Benchmrk studies (68 ) , and the protocol 005 study (92 ) . Our findings confirm the low genetic barrier % 3 6 % 7 of raltegravir. The low genetic barrier may have an influence on future drug options especially in comparable patients, as cross-resistance to elvitegravir and other integrase inhibitors under investigation have already been reported . 8
PK parameters did not provide a statistically meaningful predictive value for virological success, probably due to the fact that observed C values were quite homogeneous and exceeded the IC of raltegravir in all patients. Etravirine co-prescription did not influence min 95
raltegravir PK parameters, confirming the negligible PK interaction between etravirine and raltegravir observed in healthy subjects . HIV-1 RNA: difference of HIV-1 RNA between baseline and W4, W12 and W24, respectively. * HIV-1 RNA level less than 2.7 log copies/mL at W12 and HIV-1 RNA level less than 1.7 log copies/mL at W24, patients with missing data at W24 and HIV-1 RNA level less than 2.7 log 10 10 10 copies/mL at W12 were considered with virologic success; One patient had neither a HIV-1 RNA value at W12 nor at W24.
